MUMBAI, India, Feb. 13 -- Intellectual Property India has published a patent application (202521007243 A) filed by Ms. Vaibhavi Prashant Bharatia, Valsad, Gujarat, on Jan. 29, 2025, for 'eslicarbamazepine acetate nanosuspension formulation for treating epilepsy and method of preparing thereof.'
Inventor(s) include Ms. Vaibhavi Prashant Bharatia.
The application for the patent was published on Feb. 13, under issue no. 07/2026.
According to the abstract released by the Intellectual Property India: "Eslicarbamazepine acetate nanosuspension formulation for treating epilepsy and method of preparing thereof is described herein. The intranasal nanosuspension insitu gel formulation of eslicarbamazepine acetate comprises 50-80 mg % of eslicarbamazepine acetate, 0.1-0.22 % w/v of poloxamer 407, 0.1-0.22 % w/v of poloxamer 188, 1-5 % w/v of glycerol, 35-45 % w/v of gellan gum, 50-55 % w/v of HPMC K4M, 0.5-1.0 % w/v of NaCl, 0.005-0.01 % w/v of benzalkonium chloride and distilled water for quantity sufficient. The eslicarbamazepine acetate used as an anticonvulsant. The eslicarbamazepine acetate ensures targeted release in the brain through intranasal route, which helps in the treatment of epilepsy. The olfactory lobe can be an appropriate route for delivery of drug to brain, as it avoids blood brain barrier to reach brain."
Disclaimer: Curated by HT Syndication.
